Last reviewed · How we verify

NCT05856812: BOBUINCA

BOrrelia BUrgdorferi IN Children and Adolescents

Completed Last updated 26 November 2024
What this trial tests

trial in B. Burgdorferi Infection in 962 participants. Completed in 6 February 2024.

Timeline
23 June 2023
Primary endpoint
6 February 2024
6 February 2024

Quick facts

Lead sponsorUniversity Children's Hospital Basel
StatusCompleted
Study typeOBSERVATIONAL
Enrollment962
Start date23 June 2023
Primary completion6 February 2024
Estimated completion6 February 2024
Sites1 location across Switzerland

Conditions studied

Sponsor

University Children's Hospital Basel

Who can join

Adults 1 to 17, any sex, with B. Burgdorferi Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess B. burgdorferi antibodies in children and adolescents in north-western Switzerland and neighbouring countries ("Triregio") treated at the University Children's Hospital Basel to define age-dependent B. burgdorferi seroprevalence rates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Children's Hospital Basel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05856812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing